Enterome
Jan Fagerberg has extensive experience in the field of medical oncology. Jan is currently serving as the Chief Medical Officer at Enterome since January 2019. Prior to this, they worked as a Senior Adviser at Fagerberg Oncology - SA from August 2017 to December 2018. From December 2013 to July 2017, they held the position of Chief Medical Officer at SOTIO. In June 2013, they briefly worked as the Chief Medical Officer at ISA Pharmaceuticals. Additionally, they have worked as a Senior Adviser at Fagerberg Oncology - Senior Advisors, providing strategic consulting regarding the development of oncology drugs. Jan has also served as the VP Global Development at Amgen from March 2012 to February 2013. Before that, they held the position of Chief Medical Officer at Micromet from November 2009 to March 2012. Jan has also worked as the Medical Director at TopoTarget A/S from November 2006 to October 2009. Jan'sprevious experience includes working as a Therapeutic Area Expert - Oncology at Roche from August 1999 to October 2006 and holding multiple positions at the Department of Oncology in Karolinska Hospital from May 1990 to April 2000.
Jan Fagerberg obtained their MD degree from Karolinska Institutet between 1982 and 1988. Jan then pursued further education and achieved a PhD in Oncology - Immunology from the same institution from 1990 to 1995.
This person is not in the org chart
Enterome
Enterome’s OncoMimic technology allows the overcoming of immune tolerance against cancer cells, with broad applicability against solid tumor via an off-the-shelf, easy to manufacture technology. Enterome’s potentially first-in-class small protein and peptide drug candidates modulate the immune system by closely mimicking the structure, effect oractions of Tumor Associated Antigens to induce a potent, endogenous CD8 T cell response. The company’s most advanced programs are in Phase 2 clinical trials in hard-to-treat tumors such as glioblastoma, adrenal malignancies and colorectal cancer.